<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7464234\results\search\disease\results.xml">
  <result pre="with the advent of the new more pathogenic CoVs, including" exact="Severe" post="Acute Respiratory Syndome (SARS-CoV-1), Middle Eastern respiratory syndrome (MERS)-CoV,"/>
  <result pre="the advent of the new more pathogenic CoVs, including Severe" exact="Acute" post="Respiratory Syndome (SARS-CoV-1), Middle Eastern respiratory syndrome (MERS)-CoV, and"/>
  <result pre="advent of the new more pathogenic CoVs, including Severe Acute" exact="Respiratory" post="Syndome (SARS-CoV-1), Middle Eastern respiratory syndrome (MERS)-CoV, and the"/>
  <result pre="pathogenic CoVs, including Severe Acute Respiratory Syndome (SARS-CoV-1), Middle Eastern" exact="respiratory" post="syndrome (MERS)-CoV, and the new zoonotic SARS-CoV-2, likely originated"/>
  <result pre="CoVs, including Severe Acute Respiratory Syndome (SARS-CoV-1), Middle Eastern respiratory" exact="syndrome" post="(MERS)-CoV, and the new zoonotic SARS-CoV-2, likely originated from"/>
  <result pre="originated from bat species and responsible for the present coronavirus" exact="disease" post="(COVID-19), which to date has caused 15,581,007 confirmed cases"/>
  <result pre="Italy. SARS-CoV-2 transmission is mainly airborne via droplets generated by" exact="symptomatic" post="patients, and possibly asymptomatic individuals during incubation of the"/>
  <result pre="there are no certain data yet. However, research on asymptomatic" exact="viral infection" post="is currently ongoing worldwide to elucidate the real prevalence"/>
  <result pre="are no certain data yet. However, research on asymptomatic viral" exact="infection" post="is currently ongoing worldwide to elucidate the real prevalence"/>
  <result pre="by SARS-CoV-2 develop a mild disease/infection, 13.8% severe pneumonia, 4.7%" exact="respiratory" post="failure, septic shock, or multi-organ failure, and 3% of"/>
  <result pre="develop a mild disease/infection, 13.8% severe pneumonia, 4.7% respiratory failure," exact="septic shock," post="or multi-organ failure, and 3% of these cases are"/>
  <result pre="is highly variable in different countries. Clinically, SARS-CoV-2 causes severe" exact="primary" post="interstitial viral pneumonia and a â€œcytokine storm syndromeâ€�, characterized"/>
  <result pre="variable in different countries. Clinically, SARS-CoV-2 causes severe primary interstitial" exact="viral pneumonia" post="and a â€œcytokine storm syndromeâ€�, characterized by a severe"/>
  <result pre="in different countries. Clinically, SARS-CoV-2 causes severe primary interstitial viral" exact="pneumonia" post="and a â€œcytokine storm syndromeâ€�, characterized by a severe"/>
  <result pre="a â€œcytokine storm syndromeâ€�, characterized by a severe and fatal" exact="uncontrolled" post="systemic inflammatory response triggered by the activation of interleukin"/>
  <result pre="â€œcytokine storm syndromeâ€�, characterized by a severe and fatal uncontrolled" exact="systemic" post="inflammatory response triggered by the activation of interleukin 6"/>
  <result pre="of interleukin 6 (IL-6) with development of endothelitis and generalized" exact="thrombosis" post="that can lead to organ failure and death. Risk"/>
  <result pre="factors include advanced age and comorbidities including hypertension, diabetes, and" exact="cardiovascular disease." post="Virus entry occurs via binding the angiotensin-converting enzyme 2"/>
  <result pre="tissues and organs through the Spike (S) protein. Currently, SARS-CoV-2" exact="infection" post="is prevented by the use of masks, social distancing,"/>
  <result pre="used to manage the COVID-19 pandemic. SARS-CoV-2 COVID-19 cytokine storm" exact="syndrome" post="COVID-19 planet hyperinflammation endothelitis thromboembolism 1. Background Human coronaviruses"/>
  <result pre="CoV-NL63, Î²-CoVs, CoV-HKU1, and CoV-OC43 own low pathogenicity, cause mild" exact="respiratory" post="symptoms similar to a common cold, respectively [3]. Transmission"/>
  <result pre="of CoVs is usually via airborne droplets to the nasal" exact="mucosa" post="in closed environments and through close contact between people,"/>
  <result pre="touching contaminated surfaces. No other route of transmission of coronavirus" exact="infection" post="has been documented thus far. The virus replicates locally"/>
  <result pre="virus replicates locally in cells of the ciliated epithelium of" exact="respiratory" post="tract, causing cell damage and inflammation. Incidence peaks occur"/>
  <result pre="and poultry, ranging from mild to severe enteric, respiratory, and" exact="systemic" post="disease [1]. In temperate climates, respiratory CoV infections occur"/>
  <result pre="poultry, ranging from mild to severe enteric, respiratory, and systemic" exact="disease" post="[1]. In temperate climates, respiratory CoV infections occur more"/>
  <result pre="severe enteric, respiratory, and systemic disease [1]. In temperate climates," exact="respiratory" post="CoV infections occur more often in the winter and"/>
  <result pre="respiratory, and systemic disease [1]. In temperate climates, respiratory CoV" exact="infections" post="occur more often in the winter and spring than"/>
  <result pre="winter and spring than in the summer and fall. CoV" exact="infections" post="have shown to contribute as much as 35% of"/>
  <result pre="have shown to contribute as much as 35% of the" exact="total" post="respiratory viral activity during epidemics. The predominant illness associated"/>
  <result pre="shown to contribute as much as 35% of the total" exact="respiratory" post="viral activity during epidemics. The predominant illness associated with"/>
  <result pre="to contribute as much as 35% of the total respiratory" exact="viral" post="activity during epidemics. The predominant illness associated with CoVs"/>
  <result pre="during epidemics. The predominant illness associated with CoVs is an" exact="upper respiratory infection" post="with occasional cases of pneumonia in infants and young"/>
  <result pre="epidemics. The predominant illness associated with CoVs is an upper" exact="respiratory" post="infection with occasional cases of pneumonia in infants and"/>
  <result pre="The predominant illness associated with CoVs is an upper respiratory" exact="infection" post="with occasional cases of pneumonia in infants and young"/>
  <result pre="CoVs is an upper respiratory infection with occasional cases of" exact="pneumonia" post="in infants and young adults [1,4]. CoVs have also"/>
  <result pre="CoVs have also been shown to be effective in producing" exact="asthma" post="exacerbations in children, as well as chronic bronchitis in"/>
  <result pre="effective in producing asthma exacerbations in children, as well as" exact="chronic bronchitis" post="in adults and the elderly [5]. The milder forms"/>
  <result pre="in producing asthma exacerbations in children, as well as chronic" exact="bronchitis" post="in adults and the elderly [5]. The milder forms"/>
  <result pre="ancestral origins of major CoVs including 229E strain likely involve" exact="African" post="bat hosts as demonstrated by their finding in fecal"/>
  <result pre="from bats [7]. The common cold is due to a" exact="viral infection" post="of the upper respiratory tract. A total of more"/>
  <result pre="bats [7]. The common cold is due to a viral" exact="infection" post="of the upper respiratory tract. A total of more"/>
  <result pre="common cold is due to a viral infection of the" exact="upper" post="respiratory tract. A total of more than 200 cold-associated"/>
  <result pre="cold is due to a viral infection of the upper" exact="respiratory" post="tract. A total of more than 200 cold-associated viruses"/>
  <result pre="to a viral infection of the upper respiratory tract. A" exact="total" post="of more than 200 cold-associated viruses are known, and"/>
  <result pre="200 cold-associated viruses are known, and often more than one" exact="viral" post="species is involved in the infection at the same"/>
  <result pre="often more than one viral species is involved in the" exact="infection" post="at the same time. The most commonly responsible virus"/>
  <result pre="cases), a genus of Picornaviridae with 99 known serotypes; other" exact="viral" post="aetiological infectious agents include coronavirus (10â€&quot;15%) and Orthomyxoviridae (5â€&quot;15%),"/>
  <result pre="genus of Picornaviridae with 99 known serotypes; other viral aetiological" exact="infectious" post="agents include coronavirus (10â€&quot;15%) and Orthomyxoviridae (5â€&quot;15%), human parainfluenza"/>
  <result pre="include coronavirus (10â€&quot;15%) and Orthomyxoviridae (5â€&quot;15%), human parainfluenza virus, human" exact="respiratory" post="syncytial virus, adenovirus, enterovirus, and metapneumovirus. Besides, similar symptoms"/>
  <result pre="and metapneumovirus. Besides, similar symptoms can also be caused by" exact="bacterial infections" post="(Table 1). Many CoV infections are subclinical [11,12]. There"/>
  <result pre="metapneumovirus. Besides, similar symptoms can also be caused by bacterial" exact="infections" post="(Table 1). Many CoV infections are subclinical [11,12]. There"/>
  <result pre="also be caused by bacterial infections (Table 1). Many CoV" exact="infections" post="are subclinical [11,12]. There is speculation about the association"/>
  <result pre="the association of CoV with serious human diseases, such as" exact="multiple sclerosis" post="[13], hepatitis, or enteric diseases [14] in infants. However,"/>
  <result pre="the contrary, immunocompromised children may be predisposed to severe CoV" exact="infections" post="[1]. Nevertheless, until less than two decades ago, all"/>
  <result pre="SARS-CoV-1) discovered in November 2002 [12], (ii) the Middle Eastern" exact="Respiratory" post="Syndrome (MERS) CoV (MERS-CoV), first identified in Saudi Arabia"/>
  <result pre="discovered in November 2002 [12], (ii) the Middle Eastern Respiratory" exact="Syndrome" post="(MERS) CoV (MERS-CoV), first identified in Saudi Arabia in"/>
  <result pre="in Saudi Arabia in June 2012 [15], and (iii) SARS-CoV-2," exact="formerly" post="named 2019-nCoV when it was identified in December 2019"/>
  <result pre="it was identified in December 2019 after the sequencing of" exact="respiratory" post="clinical samples from patients in Wuhan, Hubei province, China"/>
  <result pre="samples from patients in Wuhan, Hubei province, China [16]. The" exact="disease" post="caused by SARS-CoV-2 is now called Coronavirus Diseases-2019 (COVID-19)."/>
  <result pre="bat to humans and the palm civets served as a" exact="secondary" post="host and reservoir for the continuation of the infection"/>
  <result pre="a secondary host and reservoir for the continuation of the" exact="infection" post="and then the SARS emergency [21]. The SARS epidemic,"/>
  <result pre="bats, but the passage to humans took place through an" exact="intermediate" post="host, civet, which is considered a food delicacy in"/>
  <result pre="mechanism of morbidity and lethality of SARS is the so-called" exact="acute" post="respiratory distress syndrome (ARDS). The virus-cell interaction occurs between"/>
  <result pre="of morbidity and lethality of SARS is the so-called acute" exact="respiratory" post="distress syndrome (ARDS). The virus-cell interaction occurs between the"/>
  <result pre="and lethality of SARS is the so-called acute respiratory distress" exact="syndrome" post="(ARDS). The virus-cell interaction occurs between the viral Spike"/>
  <result pre="respiratory distress syndrome (ARDS). The virus-cell interaction occurs between the" exact="viral" post="Spike protein, the ligand, and the human angiotensin-converting enzyme"/>
  <result pre="the Renin-Angiotensin system and a target for the treatment of" exact="hypertension" post="[22]. The Spike/ACE2 interaction triggers a violent acute inflammation"/>
  <result pre="treatment of hypertension [22]. The Spike/ACE2 interaction triggers a violent" exact="acute" post="inflammation of the lungs, leading to the formation of"/>
  <result pre="to the formation of a layer of fibrin on the" exact="pulmonary" post="alveoli, thus preventing gaseous exchange [23]. The transmission of"/>
  <result pre="been designed to fight SARS pandemic [26]. MERS (Middle East" exact="Respiratory" post="Syndrome) originated in 2012 in Saudi Arabia and then"/>
  <result pre="as CD26 (dipeptidyl-peptidase 4, DPP4), highly expressed in unciliated bronchial" exact="epithelial" post="cells and type II pneumocytes from lower bronchi and"/>
  <result pre="4, DPP4), highly expressed in unciliated bronchial epithelial cells and" exact="type II" post="pneumocytes from lower bronchi and lung cells in the"/>
  <result pre="in unciliated bronchial epithelial cells and type II pneumocytes from" exact="lower" post="bronchi and lung cells in the kidney, alveoli, small"/>
  <result pre="activated leukocytes [28]. The MERS has never disappeared and the" exact="infection" post="continues to be transmitted to humans by camelids, matt,"/>
  <result pre="sporadic cases were reported in the United Arab Emirates. The" exact="total" post="cumulative number of cases is 2499, with 861 deaths"/>
  <result pre="34%). Although the natural reservoir identifies the dromedaries as the" exact="intermediate" post="host, the exact modalities of species jumping with transmission"/>
  <result pre="defined [20,30]. Patients with MERS have, in addition to serious" exact="respiratory" post="disorders, important intestinal complications and sometimes acute renal damage"/>
  <result pre="addition to serious respiratory disorders, important intestinal complications and sometimes" exact="acute" post="renal damage [29]. This different clinical spectrum has been"/>
  <result pre="This different clinical spectrum has been related to a different" exact="viral" post="input receptor, the CD26 molecule, expressed not only by"/>
  <result pre="CD26 molecule, expressed not only by the epithelium of the" exact="lower" post="respiratory tract but also by the intestinal and renal"/>
  <result pre="molecule, expressed not only by the epithelium of the lower" exact="respiratory" post="tract but also by the intestinal and renal tract"/>
  <result pre="been developed for MERS, and measures to contain and prevent" exact="secondary" post="transmission are limited. 4. New SARS-CoV-2 Insights SARS-CoV-2 arose"/>
  <result pre="and the lack of recent foreign travel suggests that the" exact="disease" post="was already spreading among the French population at the"/>
  <result pre="2019 [32]. In Italy, the first cases of CoV 2019-nCoV" exact="infection" post="were diagnosed at the end of January in a"/>
  <result pre="were probably infected before their arrival in Italy, since the" exact="viral" post="strains sequences intermixed with Chinese isolates of the epidemic"/>
  <result pre="2020 before their arrival in Italy. Furthermore, the Chinese touristâ€™s" exact="viral" post="strains isolated in Italy clustered with other European strains"/>
  <result pre="that SARS-CoV-2 passed directly from bats to humans without the" exact="intermediate" post="host. Moreover, it cannot be excluded that for SARS-CoV-2"/>
  <result pre="similar to those found in SARS or MERS, although an" exact="intermediate" post="host was not found. However, there may be other"/>
  <result pre="including snakes, turtles [35], and pangolins that would serve as" exact="intermediate" post="hosts, as demonstrated by protein sequence alignment and phylogenetic"/>
  <result pre="[18,35,36,37,38,39,40]. Pangolins, long-snouted, ant-eating mammals, were suggested as the possible" exact="intermediate" post="hosts because coronavirus genomes from pangolins had approximately 85.5â€&quot;92.4%"/>
  <result pre="[36]. However, even if the pangolin may not be the" exact="intermediate" post="host for SARS-CoV-2, the possibility of viral recombination of"/>
  <result pre="not be the intermediate host for SARS-CoV-2, the possibility of" exact="viral" post="recombination of SARS-CoV-2 in pangolin cannot be excluded [35]."/>
  <result pre="is even 97.25% (Table 2). Currently, the main source of" exact="infection" post="is the patient with SARS-CoV-2. Patients with non-clinically evident"/>
  <result pre="infection is the patient with SARS-CoV-2. Patients with non-clinically evident" exact="disease" post="[41] or incubation [42] or convalescent [43] may also"/>
  <result pre="source of infection. There are two main routes of infection:" exact="respiratory" post="droplets and close contact. The possibility of aerosol transmission"/>
  <result pre="stage has been postulated [44]. Generally, the mouth, nose, and" exact="ocular" post="mucosa appear to be the major way of transmission."/>
  <result pre="has been postulated [44]. Generally, the mouth, nose, and ocular" exact="mucosa" post="appear to be the major way of transmission. In"/>
  <result pre="the tears through droplets and then be transferred to the" exact="respiratory" post="tract through the nasolacrimal canal. Indeed, conjunctivitis is one"/>
  <result pre="transferred to the respiratory tract through the nasolacrimal canal. Indeed," exact="conjunctivitis" post="is one of the symptoms of COVID-19, which is"/>
  <result pre="the symptoms of COVID-19, which is often indistinguishable from other" exact="viral conjunctivitis." post="Although further studies are needed, the risk of transmission"/>
  <result pre="the virus was demonstrated in tears or conjunctival secretions of" exact="symptomatic" post="patients [47]. In addition, it has not been demonstrated"/>
  <result pre="virus in the nasopharyngeal swab (NPS), oropharyngeal swab (OPS), and" exact="ocular" post="secretion [47]. The fecal-oral transmission route remains to be"/>
  <result pre="may persist in these patients even after the disappearance of" exact="respiratory" post="symptoms and when NPS/OPS are negative [50]. Some data"/>
  <result pre="mild to moderate COVID-19 pneumonia, no loss of pregnancy and" exact="premature birth" post="occurred [54]. Recent findings also suggest that there have"/>
  <result pre="which were negative for RT-PCR for SARS-CoV-2 [55]. However, the" exact="neonatal" post="diagnosis of SARS-CoV-2 should not be limited to molecular"/>
  <result pre="[55]. However, the neonatal diagnosis of SARS-CoV-2 should not be" exact="limited" post="to molecular testing, when there is also the possibility"/>
  <result pre="In fact, a recent Italian author highlighted the importance of" exact="viral" post="culture to be used in parallel with molecular techniques"/>
  <result pre="parallel with molecular techniques to detect the presence of cytopathogenic" exact="viral" post="agents, as demonstrated in an Italian 7-week-old lactating infant"/>
  <result pre="method, without any clinical suspicion and/or risk factor for SARS-CoV-2" exact="infection" post="[56]. More detailed studies will be required to confirm"/>
  <result pre="up to 2 days [57]. According to the Centers for" exact="Disease" post="Control and Prevention (https://www.cdc.gov/coronavirus/2019-nCoV/index.html), whether a person can acquire"/>
  <result pre="SARS, uses ACE2 receptor, a target for the treatment of" exact="hypertension" post="[22], to gain entry to cells. Accumulating data suggest"/>
  <result pre="Indeed, 83% of the cells expressing human ACE2 receptor are" exact="type II" post="alveolar epithelial cells, which can serve as a reservoir"/>
  <result pre="the cells expressing human ACE2 receptor are type II alveolar" exact="epithelial" post="cells, which can serve as a reservoir for viral"/>
  <result pre="alveolar epithelial cells, which can serve as a reservoir for" exact="viral" post="invasion, promoting rapid viral expansion and a vicious circle"/>
  <result pre="can serve as a reservoir for viral invasion, promoting rapid" exact="viral" post="expansion and a vicious circle of destruction of the"/>
  <result pre="spread among subjects [61]. After membrane fusion (Figure 1), the" exact="viral" post="RNA is released into the cytoplasm, facilitating its replication."/>
  <result pre="its replication. The abundant expression of the ACE2 receptor in" exact="type II" post="alveolar cells promotes a rapid viral multiplication with the"/>
  <result pre="ACE2 receptor in type II alveolar cells promotes a rapid" exact="viral" post="multiplication with the subsequent destruction of the local alveolar"/>
  <result pre="genetic and hormonal factors, to give more protection to COVID-19" exact="infection" post="and make them less susceptible [62]. Studies are underway"/>
  <result pre="is also highly expressed on the luminal surface of intestinal" exact="epithelial" post="cells, which may explain some initial disease manifestations, such"/>
  <result pre="surface of intestinal epithelial cells, which may explain some initial" exact="disease" post="manifestations, such as vomiting and diarrhea [64]. Thus, the"/>
  <result pre="may explain some initial disease manifestations, such as vomiting and" exact="diarrhea" post="[64]. Thus, the intestine might be a major entry"/>
  <result pre="site for SARS-CoV-2. However, less than 10% of children with" exact="infection" post="develop diarrhea and vomiting [65]. The infection of human"/>
  <result pre="SARS-CoV-2. However, less than 10% of children with infection develop" exact="diarrhea" post="and vomiting [65]. The infection of human gut epithelium"/>
  <result pre="of children with infection develop diarrhea and vomiting [65]. The" exact="infection" post="of human gut epithelium has important implications for fecalâ€&quot;oral"/>
  <result pre="epithelium has important implications for fecalâ€&quot;oral transmission and containment of" exact="viral" post="spread. Whether COVID-19 may have started with the consumption"/>
  <result pre="of viral spread. Whether COVID-19 may have started with the" exact="consumption" post="of bat food from the Wuhan market, the presumed"/>
  <result pre="dysfunction observed in patients. 6. SARS-CoV-2 and the Cytokine Storm" exact="Syndrome" post="Accumulating evidence suggests that SARS-CoV-2 causes an inflammatory response"/>
  <result pre="evidence suggests that SARS-CoV-2 causes an inflammatory response in the" exact="lower" post="airway, leading to lung injury (Figure 1). Collectively, the"/>
  <result pre="lung injury (Figure 1). Collectively, the virions first invade the" exact="respiratory" post="mucosa and then trigger a powerful immune response in"/>
  <result pre="injury (Figure 1). Collectively, the virions first invade the respiratory" exact="mucosa" post="and then trigger a powerful immune response in the"/>
  <result pre="that described in SARS and MERS [31,66]. CSS is an" exact="uncontrolled" post="and often fatal systemic inflammatory response, resulting from the"/>
  <result pre="and MERS [31,66]. CSS is an uncontrolled and often fatal" exact="systemic" post="inflammatory response, resulting from the release of large amounts"/>
  <result pre="death [31,67]. While the main target of CoVs is lung" exact="epithelial" post="cells, SARS-CoV-2 also infects macrophages and dendritic cells, which"/>
  <result pre="this cytokine activation can contribute to hypercoagulability, the cause of" exact="pulmonary" post="thromboembolism [66] leading to death from respiratory failure (Figure"/>
  <result pre="the cause of pulmonary thromboembolism [66] leading to death from" exact="respiratory" post="failure (Figure 1). Since the ACE2 receptor is also"/>
  <result pre="careful evaluation of the cytokineâ€™s profile of selected cohorts of" exact="symptomatic" post="COVID-19 patients, especially those with severe pneumonia and in"/>
  <result pre="selected cohorts of symptomatic COVID-19 patients, especially those with severe" exact="pneumonia" post="and in intensive care units (ICU). 7. Clinical Manifestations:"/>
  <result pre="lung damage leading to death in COVID-positive patients from severe" exact="respiratory" post="failure. Upon SARS-CoV-2 arrived in Europe and around the"/>
  <result pre="tissues involved by SARS-CoV-2 [70]. The initial stages of COVID-19" exact="infection" post="are nonspecific and include symptoms typical of multiple respiratory"/>
  <result pre="COVID-19 infection are nonspecific and include symptoms typical of multiple" exact="respiratory" post="illnesses (Table 1). Most cases are mild (81%), being"/>
  <result pre="far, 80.9% of patients infected with the virus develop mild" exact="infection" post="and include symptoms nonspecific and typical of multiple respiratory"/>
  <result pre="mild infection and include symptoms nonspecific and typical of multiple" exact="respiratory" post="illnesses, viral and bacterial. Some of these, which may"/>
  <result pre="and include symptoms nonspecific and typical of multiple respiratory illnesses," exact="viral" post="and bacterial. Some of these, which may occur simultaneously"/>
  <result pre="(Table 1). In agreement with Chinese studies, patients develop severe" exact="pneumonia" post="in 13.8% of cases, respiratory failure in 4.7%, and"/>
  <result pre="Chinese studies, patients develop severe pneumonia in 13.8% of cases," exact="respiratory" post="failure in 4.7%, and septic shock or even multi-organ"/>
  <result pre="pneumonia in 13.8% of cases, respiratory failure in 4.7%, and" exact="septic shock" post="or even multi-organ failure in 5%. Of these, 3%"/>
  <result pre="[31,70,71,72]. The cause of death among infected patients is severe" exact="respiratory" post="failure. Patients with severe presentation, closely resembles SARS-CoV-1 and/or"/>
  <result pre="failure. Patients with severe presentation, closely resembles SARS-CoV-1 and/or MERS-CoV" exact="infections" post="[73], may develop ARDS and require ICU admission, although"/>
  <result pre="therapy and assisted intubation may not be useful because of" exact="pulmonary" post="and generalized venous thromboembolism [66,74]. The range age of"/>
  <result pre="intubation may not be useful because of pulmonary and generalized" exact="venous thromboembolism" post="[66,74]. The range age of hospitalized patients is 57â€&quot;79"/>
  <result pre="an incubation period of ~5â€&quot;7 days (range 2â€&quot;14 days). The" exact="complete" post="clinical profile of COVID-19 is not fully understood. Symptoms"/>
  <result pre="most common symptoms [19,48,68,69] are fever, cough, pharyngitis, dyspnea, rarely" exact="kidney failure," post="suggesting fever is dominant, but not the main symptom"/>
  <result pre="suggesting fever is dominant, but not the main symptom of" exact="infection" post="(Figure 2). A small number of patients can have"/>
  <result pre="have headache/hemoptysis/diarrhea and even be relatively asymptomatic [42,48]. Patients with" exact="chronic" post="underlying diseases, including hypertension, cardio-cerebrovascular diseases, and diabetes or"/>
  <result pre="Patients with chronic underlying diseases, including hypertension, cardio-cerebrovascular diseases, and" exact="diabetes" post="or other conditions that may compromise their immune systems,"/>
  <result pre="compromise their immune systems, may increase the risk of SARS-CoV-2" exact="infection" post="[48]. Smoking may be a negative prognostic indicator for"/>
  <result pre="cases, in children the immune response is more balanced towards" exact="infection" post="and there is often an optimal recovery within a"/>
  <result pre="there is often an optimal recovery within a week, as" exact="respiratory" post="involvement, when present, tends to be more benign [31]."/>
  <result pre="week, as respiratory involvement, when present, tends to be more" exact="benign" post="[31]. A number of less frequent symptoms were described"/>
  <result pre="COVID-19, suggesting that SARS-CoV-2 does not remain confined to the" exact="respiratory" post="tract. These symptoms, often underestimated, are the feeling of"/>
  <result pre="nose, headache, myalgia, asthenia, chills, vomiting, and nausea [70]. The" exact="central nervous system" post="may be affected with headache, nausea, vomiting, instability, ideomotor"/>
  <result pre="with headache, nausea, vomiting, instability, ideomotor slowdown, ataxia, epilepsy; the" exact="peripheral" post="nervous system with hypogeusia, hyposmia, and neuralgia and the"/>
  <result pre="nervous system with hypogeusia, hyposmia, and neuralgia and the skeletal" exact="muscle" post="system may also be affected [31,70,77,78]. Moreover, cases of"/>
  <result pre="[31,70,77,78]. Moreover, cases of encephalopathy, encephalitis, necrotizing hemorrhagic encephalopathy, stroke," exact="epileptic seizures," post="rhabdomyolysis, and Guillain-Barre syndrome have been reported to be"/>
  <result pre="encephalopathy, encephalitis, necrotizing hemorrhagic encephalopathy, stroke, epileptic seizures, rhabdomyolysis, and" exact="Guillain-Barre syndrome" post="have been reported to be associated with SARS-CoV-2 infection"/>
  <result pre="encephalitis, necrotizing hemorrhagic encephalopathy, stroke, epileptic seizures, rhabdomyolysis, and Guillain-Barre" exact="syndrome" post="have been reported to be associated with SARS-CoV-2 infection"/>
  <result pre="Guillain-Barre syndrome have been reported to be associated with SARS-CoV-2" exact="infection" post="[44,79]. The neuroinvasive propensity of SARS-CoV-2 has, therefore, already"/>
  <result pre="already been documented in SARS and MERS studies [20,29]. Cardiovascular" exact="disease" post="appears to be a multiplier of the risk of"/>
  <result pre="patients who are more at risk of complications, such as" exact="myocardial infarction," post="heart failure, myocarditis, arrhythmias, and adverse outcomes [80]. Regarding"/>
  <result pre="are more at risk of complications, such as myocardial infarction," exact="heart" post="failure, myocarditis, arrhythmias, and adverse outcomes [80]. Regarding laboratory"/>
  <result pre="erythrocyte sedimentation rate, and decreased oxygenation index. Moreover, elevated levels" exact="of liver" post="function, renal function, and D-dimer (25.9%) also observed. Only"/>
  <result pre="had leukocytosis and elevated procalcitonin [31,48,70,77]. 8. Diagnosis of SARS-CoV-2" exact="Infection" post="SARS-Cov-2 infection diagnosis is mostly performed by the reverse"/>
  <result pre="and elevated procalcitonin [31,48,70,77]. 8. Diagnosis of SARS-CoV-2 Infection SARS-Cov-2" exact="infection" post="diagnosis is mostly performed by the reverse transcription polymerase"/>
  <result pre="by the reverse transcription polymerase chain reaction (RT-PCR) assay for" exact="viral" post="RNA detection, according to the US Centers for Disease"/>
  <result pre="for viral RNA detection, according to the US Centers for" exact="Disease" post="Control and Prevention instructions. Although this is the most"/>
  <result pre="sputum or bronchial lavage or the mucus/catarrh excreted from the" exact="lower" post="airway are thought to be more accurate than NPS/OPS"/>
  <result pre="swabs and blood from 16 patients in Hubei Province, and" exact="viral" post="load in throat swabs and sputum from 17 confirmed"/>
  <result pre="moment of the presence of the virus and if a" exact="symptomatic" post="subject or subject with few symptoms is negative, the"/>
  <result pre="be used in diagnosis of COVID-19 and to monitor the" exact="disease" post="stages and identify past infection and immunity [83,86]. So"/>
  <result pre="COVID-19 and to monitor the disease stages and identify past" exact="infection" post="and immunity [83,86]. So far, it remains to be"/>
  <result pre="the diagnosis and monitoring of COVID-19, especially for patients with" exact="acute" post="infection. Currently, these tests have limitations as diagnostic tools"/>
  <result pre="and Veneto. Initially in Italy, NPS/OPS were carried out on" exact="symptomatic" post="subjects only. When the infection spread to other Italian"/>
  <result pre="NPS/OPS were carried out on symptomatic subjects only. When the" exact="infection" post="spread to other Italian regions including Veneto, it became"/>
  <result pre="Performing more NPS/OPS and analyzing the correlation between NPS/OPS and" exact="symptomatic" post="patients and isolated patients at home, the number of"/>
  <result pre="district in which they live. If the pathogenesis of the" exact="disease" post="had been known early on and if this policy"/>
  <result pre="to prevent the evolution of complications, such as thromboembolism and" exact="respiratory" post="failure, thus limiting hospital admissions and potential deaths. 10."/>
  <result pre="understanding of the pathogenesis and the clinical features of this" exact="viral" post="disease. However, there are various COVID-19 aspects that remain"/>
  <result pre="The lack of knowledge of the exact molecular mechanism of" exact="viral" post="entry and replication, which provides the basis for future"/>
  <result pre="know why the male gender is more affected than the" exact="female" post="gender. Genetic hormonal differences have been reported, and testosterone"/>
  <result pre="testosterone seems to favor a more severe evolution of the" exact="infection" post="in some cases. In this context, females seem to"/>
  <result pre="genetic and hormonal factors, to give more protection to SARS-CoV-2" exact="infection" post="and make them less susceptible [62]. Studies are underway"/>
  <result pre="the proportion is closer to 5% [90,91]. Research of asymptomatic" exact="infection" post="among swab positive persons is currently ongoing worldwide to"/>
  <result pre="currently ongoing worldwide to elucidate the real prevalence of the" exact="disease" post="and the true relative mortality ratio. Recently, no statistically"/>
  <result pre="ratio. Recently, no statistically significant difference was found in the" exact="viral" post="load of symptomatic versus asymptomatic infections, highlighting the importance"/>
  <result pre="statistically significant difference was found in the viral load of" exact="symptomatic" post="versus asymptomatic infections, highlighting the importance of asymptomatic SARS-CoV-2"/>
  <result pre="symptomatic versus asymptomatic infections, highlighting the importance of asymptomatic SARS-CoV-2" exact="infection" post="[92]. Moreover, asymptomatic individuals have shown a weaker immune"/>
  <result pre="distributed to patients. The search for effective treatments for COVID-19" exact="infection" post="is a complex process and not all are recommended"/>
  <result pre="a complex process and not all are recommended in the" exact="absence of" post="clear evidence of proven efficacy. SARS-CoV-2 owns potential therapeutic"/>
  <result pre="treatment of COVID-19 in adults and children hospitalized with severe" exact="disease" post="[96]. The mechanism of action of RDV makes it"/>
  <result pre="but fewer than a quarter are double-blind, and some are" exact="uncontrolled" post="observational studies [97]. Although measurement of efficacy will require"/>
  <result pre="to administer RDV by aerosol to combat SARS-CoV-2 in the" exact="upper" post="respiratory tract in patients with severe clinical conditions and"/>
  <result pre="administer RDV by aerosol to combat SARS-CoV-2 in the upper" exact="respiratory" post="tract in patients with severe clinical conditions and in"/>
  <result pre="in ICUs in order to avoid possible side effects of" exact="systemic" post="intravenous RDV administration [98]. Other recent potential effective antivirals"/>
  <result pre="for antiviral therapies, which interrupt the nucleotide incorporation process during" exact="viral" post="RNA replication [90]. Favipiravir is a guanine analog approved"/>
  <result pre="Favipiravir is a guanine analog approved for treatment against influenza" exact="virus infection" post="in Japan and also can effectively inhibit replication of"/>
  <result pre="is a guanine analog approved for treatment against influenza virus" exact="infection" post="in Japan and also can effectively inhibit replication of"/>
  <result pre="in Japan and also can effectively inhibit replication of Ebola," exact="yellow fever," post="chikungunya, norovirus, and enterovirus and could potentially exhibit effects"/>
  <result pre="contributes to mortality [101]. Tocilizumab has been widely used in" exact="rheumatic" post="diseases, such as rheumatoid arthritis. It is an IL-6"/>
  <result pre="Tocilizumab has been widely used in rheumatic diseases, such as" exact="rheumatoid arthritis." post="It is an IL-6 receptor (IL-6R) blocker that can"/>
  <result pre="died. Antagonists of Proteinases. The growing recognition of endothelitis and" exact="thrombosis" post="in COVID-19 patients provides a strong incentive to determine"/>
  <result pre="of hyperimmune plasma obtained from convalescent patients recovered from the" exact="disease" post="has shown to be a very promising and specific"/>
  <result pre="very promising and specific approach for the treatment of SARS-COV-2" exact="infection" post="[104]. This could represent a promising specific approach in"/>
  <result pre="the basis of experience gained in other countries on a" exact="limited" post="number of patients [105]. Convalescent plasma therapy also appears"/>
  <result pre="far, there is general consensus on the importance of combating" exact="uncontrolled" post="inflammation, and the resulting ARDS or CSS, caused by"/>
  <result pre="currently emerged as one of the most intense and overwhelming" exact="viral infection" post="for the humankind to manage. As the number of"/>
  <result pre="emerged as one of the most intense and overwhelming viral" exact="infection" post="for the humankind to manage. As the number of"/>
  <result pre="selected cohorts of subjects, which include SARS-CoV-2 positive patients with" exact="pneumonia" post="or admitted to ICU. COVID-19 clinical evidence has shown"/>
  <result pre="published version of the manuscript. Funding This research received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
  <result pre="Top. Microbiol. Immunol.19746385129 2.WeissS.R.Navas-MartinS.Coronavirus pathogenesis and the emerging pathogen severe" exact="acute" post="respiratory syndrome coronavirusMicrobiol. Mol. Biol. Rev.20056963566410.1128/MMBR.69.4.635-664.200516339739 3.MeulenV.Biology of coronavirusesAdv."/>
  <result pre="Microbiol. Immunol.19746385129 2.WeissS.R.Navas-MartinS.Coronavirus pathogenesis and the emerging pathogen severe acute" exact="respiratory" post="syndrome coronavirusMicrobiol. Mol. Biol. Rev.20056963566410.1128/MMBR.69.4.635-664.200516339739 3.MeulenV.Biology of coronavirusesAdv. Exp."/>
  <result pre="Immunol.19746385129 2.WeissS.R.Navas-MartinS.Coronavirus pathogenesis and the emerging pathogen severe acute respiratory" exact="syndrome" post="coronavirusMicrobiol. Mol. Biol. Rev.20056963566410.1128/MMBR.69.4.635-664.200516339739 3.MeulenV.Biology of coronavirusesAdv. Exp. Med."/>
  <result pre="Mol. Biol. Rev.20056963566410.1128/MMBR.69.4.635-664.200516339739 3.MeulenV.Biology of coronavirusesAdv. Exp. Med. Biol.19841732272356331113 4.WenzelR.P.HendleyJ.O.DaviesJ.A.GwaltneyJ.M.Jr.Coronavirus" exact="infections" post="in military recruits. Three-year study with coronavirus strains OC43"/>
  <result pre="strains OC43 and 229EAm. Rev. Respir. Dis.19741096216244365165 5.Van BeverH.P.ChngS.Y.GohD.Y.Childhood severe" exact="acute" post="respiratory syndrome, coronavirus infections and asthmaPediatr. Allergy. Immunol.20041520620910.1111/j.1399-3038.2004.00137.x15209951 6.PfefferleS.OppongS.DrexlerJ.F.Gloza-RauschF.IpsenA.SeebensA.MullerM.A.AnnanA.ValloP.Adu-SarkodieY.et"/>
  <result pre="OC43 and 229EAm. Rev. Respir. Dis.19741096216244365165 5.Van BeverH.P.ChngS.Y.GohD.Y.Childhood severe acute" exact="respiratory" post="syndrome, coronavirus infections and asthmaPediatr. Allergy. Immunol.20041520620910.1111/j.1399-3038.2004.00137.x15209951 6.PfefferleS.OppongS.DrexlerJ.F.Gloza-RauschF.IpsenA.SeebensA.MullerM.A.AnnanA.ValloP.Adu-SarkodieY.et al.Distant"/>
  <result pre="Rev. Respir. Dis.19741096216244365165 5.Van BeverH.P.ChngS.Y.GohD.Y.Childhood severe acute respiratory syndrome, coronavirus" exact="infections" post="and asthmaPediatr. Allergy. Immunol.20041520620910.1111/j.1399-3038.2004.00137.x15209951 6.PfefferleS.OppongS.DrexlerJ.F.Gloza-RauschF.IpsenA.SeebensA.MullerM.A.AnnanA.ValloP.Adu-SarkodieY.et al.Distant relatives of severe"/>
  <result pre="infections and asthmaPediatr. Allergy. Immunol.20041520620910.1111/j.1399-3038.2004.00137.x15209951 6.PfefferleS.OppongS.DrexlerJ.F.Gloza-RauschF.IpsenA.SeebensA.MullerM.A.AnnanA.ValloP.Adu-SarkodieY.et al.Distant relatives of severe" exact="acute" post="respiratory syndrome coronavirus and close relatives of human coronavirus"/>
  <result pre="and asthmaPediatr. Allergy. Immunol.20041520620910.1111/j.1399-3038.2004.00137.x15209951 6.PfefferleS.OppongS.DrexlerJ.F.Gloza-RauschF.IpsenA.SeebensA.MullerM.A.AnnanA.ValloP.Adu-SarkodieY.et al.Distant relatives of severe acute" exact="respiratory" post="syndrome coronavirus and close relatives of human coronavirus 229E"/>
  <result pre="asthmaPediatr. Allergy. Immunol.20041520620910.1111/j.1399-3038.2004.00137.x15209951 6.PfefferleS.OppongS.DrexlerJ.F.Gloza-RauschF.IpsenA.SeebensA.MullerM.A.AnnanA.ValloP.Adu-SarkodieY.et al.Distant relatives of severe acute respiratory" exact="syndrome" post="coronavirus and close relatives of human coronavirus 229E in"/>
  <result pre="human infectionsFuture Microbiol.2007237337610.2217/17460913.2.4.37317683273 11.ZhangN.WangL.DengX.LiangR.SuM.HeC.HuL.SuY.RenJ.YuF.et al.Recent advances in the detection of" exact="respiratory" post="virus infection in humansJ. Med. Virol.20209240841710.1002/jmv.2567431944312 12.collab: World Health"/>
  <result pre="infectionsFuture Microbiol.2007237337610.2217/17460913.2.4.37317683273 11.ZhangN.WangL.DengX.LiangR.SuM.HeC.HuL.SuY.RenJ.YuF.et al.Recent advances in the detection of respiratory" exact="virus infection" post="in humansJ. Med. Virol.20209240841710.1002/jmv.2567431944312 12.collab: World Health OrganizationConsensus Document"/>
  <result pre="Microbiol.2007237337610.2217/17460913.2.4.37317683273 11.ZhangN.WangL.DengX.LiangR.SuM.HeC.HuL.SuY.RenJ.YuF.et al.Recent advances in the detection of respiratory virus" exact="infection" post="in humansJ. Med. Virol.20209240841710.1002/jmv.2567431944312 12.collab: World Health OrganizationConsensus Document"/>
  <result pre="Virol.20209240841710.1002/jmv.2567431944312 12.collab: World Health OrganizationConsensus Document on the Epidemiology of" exact="Severe" post="Acute Respiratory Syndrome (SARS)World Health OrganizationGeneva, Switzerland2003Available online: http://tdr.who.int/csr/sars/WHOconsensus.pdf(accessed"/>
  <result pre="12.collab: World Health OrganizationConsensus Document on the Epidemiology of Severe" exact="Acute" post="Respiratory Syndrome (SARS)World Health OrganizationGeneva, Switzerland2003Available online: http://tdr.who.int/csr/sars/WHOconsensus.pdf(accessed on"/>
  <result pre="World Health OrganizationConsensus Document on the Epidemiology of Severe Acute" exact="Respiratory" post="Syndrome (SARS)World Health OrganizationGeneva, Switzerland2003Available online: http://tdr.who.int/csr/sars/WHOconsensus.pdf(accessed on 10"/>
  <result pre="Health OrganizationConsensus Document on the Epidemiology of Severe Acute Respiratory" exact="Syndrome" post="(SARS)World Health OrganizationGeneva, Switzerland2003Available online: http://tdr.who.int/csr/sars/WHOconsensus.pdf(accessed on 10 June"/>
  <result pre="online: http://tdr.who.int/csr/sars/WHOconsensus.pdf(accessed on 10 June 2020) 13.BurksJ.S.DeValdB.L.JankovskyL.D.GerdesJ.Two coronaviruses isolated from" exact="central nervous system" post="tissue of two multiple sclerosis patientsScience198020993393410.1126/science.74038607403860 14.RestaS.LubyJ.P.RosenfiledC.R.SiegelJ.D.Isolation and propagation"/>
  <result pre="13.BurksJ.S.DeValdB.L.JankovskyL.D.GerdesJ.Two coronaviruses isolated from central nervous system tissue of two" exact="multiple sclerosis" post="patientsScience198020993393410.1126/science.74038607403860 14.RestaS.LubyJ.P.RosenfiledC.R.SiegelJ.D.Isolation and propagation of a human enteric coronavirusScience198522997898110.1126/science.29920912992091"/>
  <result pre="15.ZakiA.M.van BoheemenS.BestebroerT.M.OsterhausA.D.FouchierR.A.Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN. Engl. J. Med.20123671814182010.1056/NEJMoa121172123075143 16.collab: WHOCoronavirus Disease"/>
  <result pre="with pneumonia in Saudi ArabiaN. Engl. J. Med.20123671814182010.1056/NEJMoa121172123075143 16.collab: WHOCoronavirus" exact="Disease" post="(COVID-19) OutbreakAvailable online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019(accessed on 29 February 2020) 17.ZhaiS.L.WeiW.K.LvD.H.XuZ.H.ChenQ.L.SunM.F.LiF.WangD.Where"/>
  <result pre="by international air travelEpidemiol. Infect.20091371019103110.1017/S095026880800163519079846 25.DingY.HeL.ZhangQ.HuangZ.CheX.HouJ.WangH.ShenH.QiuL.LiZ.et al.Organ distribution of severe" exact="acute" post="respiratory syndrome(SARS) associated coronavirus (SARS-CoV) in SARS patients: Implications"/>
  <result pre="international air travelEpidemiol. Infect.20091371019103110.1017/S095026880800163519079846 25.DingY.HeL.ZhangQ.HuangZ.CheX.HouJ.WangH.ShenH.QiuL.LiZ.et al.Organ distribution of severe acute" exact="respiratory" post="syndrome(SARS) associated coronavirus (SARS-CoV) in SARS patients: Implications for"/>
  <result pre="infected dromedary camels in Saudi Arabia 2018â€&quot;2019Virus Dis.202061410.1007/s13337-020-00586-y 29.RamadanN.ShaibH.Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV)Germs20199354210.18683/germs.2019.115531119115 30.IslamA.EpsteinJ.H.RostalM.K.IslamS.RahmanM.Z.HossainM.E.UzzamanM.S.MunsterV.J.PeirisM.FloraM.S.et al.Middle East respiratory syndrome coronavirus"/>
  <result pre="dromedary camels in Saudi Arabia 2018â€&quot;2019Virus Dis.202061410.1007/s13337-020-00586-y 29.RamadanN.ShaibH.Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV)Germs20199354210.18683/germs.2019.115531119115 30.IslamA.EpsteinJ.H.RostalM.K.IslamS.RahmanM.Z.HossainM.E.UzzamanM.S.MunsterV.J.PeirisM.FloraM.S.et al.Middle East respiratory syndrome coronavirus in"/>
  <result pre="Dis.202061410.1007/s13337-020-00586-y 29.RamadanN.ShaibH.Middle East respiratory syndrome coronavirus (MERS-CoV)Germs20199354210.18683/germs.2019.115531119115 30.IslamA.EpsteinJ.H.RostalM.K.IslamS.RahmanM.Z.HossainM.E.UzzamanM.S.MunsterV.J.PeirisM.FloraM.S.et al.Middle East" exact="respiratory" post="syndrome coronavirus in dromedary camels: An outbreak investigationLancet Infect."/>
  <result pre="29.RamadanN.ShaibH.Middle East respiratory syndrome coronavirus (MERS-CoV)Germs20199354210.18683/germs.2019.115531119115 30.IslamA.EpsteinJ.H.RostalM.K.IslamS.RahmanM.Z.HossainM.E.UzzamanM.S.MunsterV.J.PeirisM.FloraM.S.et al.Middle East respiratory" exact="syndrome" post="coronavirus in dromedary camels: An outbreak investigationLancet Infect. Dis.20141414014524355866"/>
  <result pre="of coronavirus spike proteins and host ACE2 receptors predict potential" exact="intermediate" post="hosts of SARS-CoV-2J. Med. Virol.20209259560110.1002/jmv.2572632100877 36.LamT.T.ShumM.H.ZhuH.C.TongY.G.NiX.B.LiaoY.S.WeiW.CheungW.Y.M.LiW.J.LiL.F.et al.Identification of 2019-nCoV"/>
  <result pre="ChinaNature202010.1038/s41586-020-2169-0 37.RotaP.A.ObersteM.S.MonroeS.S.NixW.A.CampagnoliR.IcenogleJ.P.PeÃ±arandaS.BankampB.MaherK.ChenM.H.et al.Characterization of a novel coronavirus associated with severe" exact="acute" post="respiratory syndromeScience20033001394139910.1126/science.108595212730500 38.Van BoheemenS.de GraafM.LauberC.BestebroerT.M.RajS.V.ZakiA.M.OsterhausA.D.M.E.HaagmansB.L.GorbalenyaA.E.SnijderE.J.et al.Genomic characterization of a"/>
  <result pre="37.RotaP.A.ObersteM.S.MonroeS.S.NixW.A.CampagnoliR.IcenogleJ.P.PeÃ±arandaS.BankampB.MaherK.ChenM.H.et al.Characterization of a novel coronavirus associated with severe acute" exact="respiratory" post="syndromeScience20033001394139910.1126/science.108595212730500 38.Van BoheemenS.de GraafM.LauberC.BestebroerT.M.RajS.V.ZakiA.M.OsterhausA.D.M.E.HaagmansB.L.GorbalenyaA.E.SnijderE.J.et al.Genomic characterization of a newly"/>
  <result pre="GraafM.LauberC.BestebroerT.M.RajS.V.ZakiA.M.OsterhausA.D.M.E.HaagmansB.L.GorbalenyaA.E.SnijderE.J.et al.Genomic characterization of a newly discovered coronavirus associated with" exact="acute" post="respiratory distress syndrome in humansmBio201231910.1128/mBio.00473-12 39.WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.HuY.TaoZ.W.TianJ.H.PeiY.Y.et al.A new coronavirus"/>
  <result pre="al.Genomic characterization of a newly discovered coronavirus associated with acute" exact="respiratory" post="distress syndrome in humansmBio201231910.1128/mBio.00473-12 39.WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.HuY.TaoZ.W.TianJ.H.PeiY.Y.et al.A new coronavirus associated"/>
  <result pre="of a newly discovered coronavirus associated with acute respiratory distress" exact="syndrome" post="in humansmBio201231910.1128/mBio.00473-12 39.WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.HuY.TaoZ.W.TianJ.H.PeiY.Y.et al.A new coronavirus associated with human"/>
  <result pre="syndrome in humansmBio201231910.1128/mBio.00473-12 39.WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.HuY.TaoZ.W.TianJ.H.PeiY.Y.et al.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature202057926526910.1038/s41586-020-2008-332015508 40.LescureF.X.BouadmaL.NguyenD.PariseyM.WickyP.H.BehillilS.GaymardA.Bouscambert-DuchampM.DonatiF.Le HingratQ.et al.Clinical and virological data"/>
  <result pre="in humansmBio201231910.1128/mBio.00473-12 39.WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.HuY.TaoZ.W.TianJ.H.PeiY.Y.et al.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature202057926526910.1038/s41586-020-2008-332015508 40.LescureF.X.BouadmaL.NguyenD.PariseyM.WickyP.H.BehillilS.GaymardA.Bouscambert-DuchampM.DonatiF.Le HingratQ.et al.Clinical and virological data of"/>
  <result pre="Europe: A case seriesLancet Infect. Dis.20202069770610.1016/S1473-3099(20)30200-032224310 41.HoehlS.RabenauH.BergerA.KortenbuschM.CinatlJ.BojkovaD.BehrensP.BÃ¶ddinghausB.GÃ¶tschU.NaujoksF.et al.Evidence of SARS-CoV-2" exact="infection" post="in returning travelers from Wuhan, ChinaN. Engl. J. Med.20203821278128010.1056/NEJMc200189932069388"/>
  <result pre="from Wuhan, ChinaN. Engl. J. Med.20203821278128010.1056/NEJMc200189932069388 42.RotheC.SchunkM.SothmannP.Gisela BretzelG.FroeschlG.WallrauchC.ZimmerT.ThielV.Transmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in GermanyN. Engl. J. Med.202038297097110.1056/NEJMc200146832003551"/>
  <result pre="neuroinvasive potential of SARS-CoV2 may play a role in the" exact="respiratory" post="failure of COVID-19 patientsJ. Med. Virol.20209255255510.1002/jmv.2572832104915 45.QingH.LiZ.YangZ.ShiM.HuangZ.SongJ.SongZ.The possibility of"/>
  <result pre="United StatesN. Engl. J. Med.202038292993610.1056/NEJMoa200119132004427 50.LingY.XuS.B.LinY.X.TianD.ZhuZ.Q.DaiF.H.WuF.SongZ.G.HuangW.ChenJ.et al.Persistence and clearance of" exact="viral" post="RNA in 2019 novel coronavirus disease rehabilitation patientsChin. Med."/>
  <result pre="al.Persistence and clearance of viral RNA in 2019 novel coronavirus" exact="disease" post="rehabilitation patientsChin. Med. J.20201331039104310.1097/CM9.000000000000077432118639 51.WangW.XumY.GaoR.LuR.HanK.WuG.TanW.Detection of SARS-CoV-2 in different"/>
  <result pre="Health202011416816932407189 53.VivantiA.J.Vauloup-FellousC.PrevotS.ZupanV.SuffeeC.Do CaoJ.BenachiA.De LucaD.Transplacental transmission of SARS-CoV-2 infectionNat. Commun.202011357210.1038/s41467-020-17436-632665677 54.KasraeianM.ZareM.VafaeiH.AsadiN.FarajiA.BazrafshanK.RoozmehS.COVID-19" exact="Pneumonia" post="and Pregnancy; A Systematic Review and Meta-AnalysisJ. Matern. Fetal"/>
  <result pre="Pneumonia and Pregnancy; A Systematic Review and Meta-AnalysisJ. Matern. Fetal" exact="Neonatal" post="Med.20201810.1080/14767058.2020.176395232429786 55.SchwartzD.A.An analysis of 38 pregnant women with COVID-19,"/>
  <result pre="their newborn infants, and maternal-fetal transmisssion of SARS-CoV-2: Maternal coronavirus" exact="infections" post="and pregnancy outcomesArch. Pathol. Lab. Med.202010.5858/arpa.2020-0901-SA 56.CalderaroA.ArcangelettimM.C.De ContoF.ButtriniM.MontagnaP.MontecchiniS.FerragliaF.PinardiF.ChezziC.SARS-CoV-2 infection"/>
  <result pre="coronavirus infections and pregnancy outcomesArch. Pathol. Lab. Med.202010.5858/arpa.2020-0901-SA 56.CalderaroA.ArcangelettimM.C.De ContoF.ButtriniM.MontagnaP.MontecchiniS.FerragliaF.PinardiF.ChezziC.SARS-CoV-2" exact="infection" post="diagnosed only by cell culture isolation before the local"/>
  <result pre="their inactivation with biocidal agentsJ. Hosp. Infect.202010424625110.1016/j.jhin.2020.01.02232035997 58.RameshN.SiddaiahA.JosephB.Tackling corona virus" exact="disease" post="2019 (COVID 19) in workplacesIndian J. Occup. Environ. Med.202024161832341630"/>
  <result pre="Hepatol.20203574474810.1111/jgh.1504732215956 65.MatthaiJ.ShanmugamN.SobhanP.collab: Indian Society of pediatric gastroenterology, hepatology and nutritioncollab:" exact="Pediatric" post="Gastroenterology Chapter Of Indian Academy Of Pediatrics Coronavirus Disease"/>
  <result pre="nutritioncollab: Pediatric Gastroenterology Chapter Of Indian Academy Of Pediatrics Coronavirus" exact="Disease" post="(COVID-19) and the Gastrointestinal System in ChildrenCoronavirus Disease (COVID-19)"/>
  <result pre="Pediatrics Coronavirus Disease (COVID-19) and the Gastrointestinal System in ChildrenCoronavirus" exact="Disease" post="(COVID-19) and the Gastrointestinal System in ChildrenIndian Pediatr.20205753353510.1007/s13312-020-1851-532562397 66.XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.LiuS.ZhaoP.LiuH.ZhuL.et"/>
  <result pre="in ChildrenIndian Pediatr.20205753353510.1007/s13312-020-1851-532562397 66.XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.LiuS.ZhaoP.LiuH.ZhuL.et al.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir. Med.2020842042210.1016/S2213-2600(20)30076-X32085846 67.YeQ.WangB.MaoJ.The pathogenesis and treatment"/>
  <result pre="ChildrenIndian Pediatr.20205753353510.1007/s13312-020-1851-532562397 66.XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.LiuS.ZhaoP.LiuH.ZhuL.et al.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir. Med.2020842042210.1016/S2213-2600(20)30076-X32085846 67.YeQ.WangB.MaoJ.The pathogenesis and treatment of"/>
  <result pre="treatment of the â€˜Cytokine Stormâ€™ in COVID-19J. Infect.20208060761310.1016/j.jinf.2020.03.03732283152 68.RuscittiP.BerardicurtiO.IagnoccoA.GiacomelliR.Cytokine storm" exact="syndrome" post="in severe COVID-19Autoimmun. Rev.20201910256210.1016/j.autrev.2020.10256232376400 69.De BiasiS.MeschiariM.GibelliniL.BellinazziC.BorellaR.FidanzaL.GozziL.IannoneA.Lo TartaroD.MattioliM.et al.Marked T"/>
  <result pre="Community Health20208e00048810.1136/fmch-2020-00040632467096 71.WuZ.McGooganJ.M.Characteristics of and important lessons from the Coronavirus" exact="Disease" post="2019 (COVID-19) outbreak in China: Summary of a report"/>
  <result pre="report of 72 314 cases from the Chinese Center for" exact="Disease" post="Control and PreventionJAMA202010.1001/jama.2020.2648 72.CascellaM.RajnikM.CuomoA.DulebohnS.C.Di NapoliR.Features, Evaluation and Treatment Coronavirus"/>
  <result pre="Island, FL, USA2020 73.BadawiA.RyooS.G.Prevalence of comorbidities in the Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV): A systematic review and meta-analysisInt. J."/>
  <result pre="FL, USA2020 73.BadawiA.RyooS.G.Prevalence of comorbidities in the Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV): A systematic review and meta-analysisInt. J. Infect."/>
  <result pre="review and meta-analysisInt. J. Infect. Dis.20164912913310.1016/j.ijid.2016.06.01527352628 74.WichmannD.SperhakeJ.P.LÃ¼tgehetmannM.SteurerS.EdlerC.HeinemannA.HeinrichF.MushumbaH.KniepI.SchrÃ¶derA.S.et al.Autopsy findings and" exact="venous thromboembolism" post="in patients with COVID-19Ann. Intern. Med.2020M20-200310.7326/M20-200332374815 75.ChenJ.Pathogenicity and transmissibility"/>
  <result pre="15 April 2020) 90.CaoG.W.ZhangB.X.ChenX.P.Strategy and Policy Working Group for NCIP" exact="Epidemic" post="Response. Urgent research agenda for the novel coronavirus epidemic:"/>
  <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version)Mil. Med. Res.20207410.1186/s40779-020-0233-632029004 92.LavezzoE.FranchinE.CiavarellaC.Cuomo-DannenburgG.BarzonL.Del VecchioC.RossiL.ManganelliR.LoregianA.NavarinN.et al.Suppression of a"/>
  <result pre="status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus" exact="disease" post="2019 (COVID-19)J. Microbiol. Biotechnol.20203031332410.4014/jmb.2003.0301132238757 96.FernerR.E.AronsonJ.K.Remdesivir in covid-19BMJ2020369m161010.1136/bmj.m161032321732 97.GreinJ.OhmagariN.ShinD.DiazG.AspergesE.CastagnaA.FeldtT.GreenG.GreenM.L.LescureF.X.et al.Compassionate"/>
  <result pre="new pharmacological approach based on Remdesivir aerosolized administration on SARS-CoV-2" exact="pulmonary" post="inflammation: A possible and rational therapeutic applicationMed. Hypotheses202014410987610.1016/j.mehy.2020.10987632562915 99.FurutaY.KomenoT.NakamuraT.Favipiravir"/>
  <result pre="therapeutic applicationMed. Hypotheses202014410987610.1016/j.mehy.2020.10987632562915 99.FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProc. Jpn. Acad. Ser. B Phys. Biol. Sci.20179344946310.2183/pjab.93.02728769016"/>
  <result pre="A rapid reviewCochrane Database Syst. Rev.2020510.1002/14651858.CD013600 107.collab: European Commission Directorate" exact="General" post="for Health and Food SafetyAn EU Programme of COVID-19"/>
  <result pre="1 Angiotensin-converting enzyme 2 (ACE2) expression is also found in" exact="respiratory" post="and pulmonary tract cells (alveolar monocytes and macrophages), with"/>
  <result pre="enzyme 2 (ACE2) expression is also found in respiratory and" exact="pulmonary" post="tract cells (alveolar monocytes and macrophages), with the possibility"/>
  <result pre="cells (alveolar monocytes and macrophages), with the possibility of severe" exact="acute" post="respiratory distress syndrome (ARDS) and in heart, kidneys, brain,"/>
  <result pre="(alveolar monocytes and macrophages), with the possibility of severe acute" exact="respiratory" post="distress syndrome (ARDS) and in heart, kidneys, brain, endothelium,"/>
  <result pre="and macrophages), with the possibility of severe acute respiratory distress" exact="syndrome" post="(ARDS) and in heart, kidneys, brain, endothelium, liver, in"/>
  <result pre="the COVID-19 pandemic. microorganisms-08-01228-t001_Table 1Table 1 Most common pathogens and" exact="respiratory" post="diseases that may display symptoms similar to coronavirus diseases"/>
  <result pre="similar to coronavirus diseases (COVID)-19 include the following. Virus and" exact="Viral" post="Diseases Orthomyxovirus (Influenza) Paramyxovirus (Parainfluenza) PIV-1, -2, -3, and"/>
  <result pre="to coronavirus diseases (COVID)-19 include the following. Virus and Viral" exact="Diseases" post="Orthomyxovirus (Influenza) Paramyxovirus (Parainfluenza) PIV-1, -2, -3, and 4"/>
  <result pre="metapneumovirus * Human rhinovirus Â§ Adenovirus Coronavirus ^ Enterovirus ^^" exact="Respiratory" post="syncytial virus Â° Bacteria and Bacterial Infections Haemophilus influenzae"/>
  <result pre="Coronavirus ^ Enterovirus ^^ Respiratory syncytial virus Â° Bacteria and" exact="Bacterial Infections" post="Haemophilus influenzae pneumonia Streptococcus pneumoniae pneumonia Moraxella catarrhalis pneumonia"/>
  <result pre="^ Enterovirus ^^ Respiratory syncytial virus Â° Bacteria and Bacterial" exact="Infections" post="Haemophilus influenzae pneumonia Streptococcus pneumoniae pneumonia Moraxella catarrhalis pneumonia"/>
  <result pre="Respiratory syncytial virus Â° Bacteria and Bacterial Infections Haemophilus influenzae" exact="pneumonia" post="Streptococcus pneumoniae pneumonia Moraxella catarrhalis pneumonia Bordetella pertussis and"/>
  <result pre="syncytial virus Â° Bacteria and Bacterial Infections Haemophilus influenzae pneumonia" exact="Streptococcus pneumoniae pneumonia" post="Moraxella catarrhalis pneumonia Bordetella pertussis and Bordetella parapertussis Legionella"/>
  <result pre="Â° Bacteria and Bacterial Infections Haemophilus influenzae pneumonia Streptococcus pneumoniae" exact="pneumonia" post="Moraxella catarrhalis pneumonia Bordetella pertussis and Bordetella parapertussis Legionella"/>
  <result pre="Bacterial Infections Haemophilus influenzae pneumonia Streptococcus pneumoniae pneumonia Moraxella catarrhalis" exact="pneumonia" post="Bordetella pertussis and Bordetella parapertussis Legionella pneumophila Â°Â° Mycoplasma"/>
  <result pre="Haemophilus influenzae pneumonia Streptococcus pneumoniae pneumonia Moraxella catarrhalis pneumonia Bordetella" exact="pertussis" post="and Bordetella parapertussis Legionella pneumophila Â°Â° Mycoplasma pneumoniae Â°Â°"/>
  <result pre="pneumoniae pneumonia Moraxella catarrhalis pneumonia Bordetella pertussis and Bordetella parapertussis" exact="Legionella" post="pneumophila Â°Â° Mycoplasma pneumoniae Â°Â° Chlamydia pneumoniae Â°Â° *"/>
  <result pre="Â°Â° Mycoplasma pneumoniae Â°Â° Chlamydia pneumoniae Â°Â° * Human metapneumovirus" exact="infection" post="include pneumonia, otitis media, bronchiolitis, exacerbations of asthma, or"/>
  <result pre="Â°Â° Chlamydia pneumoniae Â°Â° * Human metapneumovirus infection include pneumonia," exact="otitis media," post="bronchiolitis, exacerbations of asthma, or chronic obstructive pulmonary disease."/>
  <result pre="metapneumovirus infection include pneumonia, otitis media, bronchiolitis, exacerbations of asthma," exact="or chronic" post="obstructive pulmonary disease. Â§ Human rhinoviruses (HRVs) consist of"/>
  <result pre="infection include pneumonia, otitis media, bronchiolitis, exacerbations of asthma, or" exact="chronic" post="obstructive pulmonary disease. Â§ Human rhinoviruses (HRVs) consist of"/>
  <result pre="pneumonia, otitis media, bronchiolitis, exacerbations of asthma, or chronic obstructive" exact="pulmonary" post="disease. Â§ Human rhinoviruses (HRVs) consist of approximately 160"/>
  <result pre="wide range of infections, including asymptomatic infections, common colds, and" exact="benign" post="or severe lower respiratory illnesses [8]. ^ Four strains"/>
  <result pre="infections, including asymptomatic infections, common colds, and benign or severe" exact="lower" post="respiratory illnesses [8]. ^ Four strains of coronavirus including"/>
  <result pre="including asymptomatic infections, common colds, and benign or severe lower" exact="respiratory" post="illnesses [8]. ^ Four strains of coronavirus including OC43,"/>
  <result pre="of more than 100 non-polio enteroviruses known today that causes" exact="respiratory" post="diseases [9]. It is found in respiratory secretions such"/>
  <result pre="today that causes respiratory diseases [9]. It is found in" exact="respiratory" post="secretions such as mucus, saliva, or sputum of an"/>
  <result pre="object or surface that is then touched by others. Â°" exact="Respiratory" post="syncytial virus is amongst the most important pathogenic infections"/>
  <result pre="Â° Respiratory syncytial virus is amongst the most important pathogenic" exact="infections" post="of childhood and is associated with significant morbidity and"/>
  <result pre="syncytial virus is amongst the most important pathogenic infections of" exact="childhood" post="and is associated with significant morbidity and mortality [8];"/>
  <result pre="associated with significant morbidity and mortality [8]; Â°Â° responsible for" exact="atypical pneumonia" post="as well as benign upper airway disorders including pharyngodinia,"/>
  <result pre="with significant morbidity and mortality [8]; Â°Â° responsible for atypical" exact="pneumonia" post="as well as benign upper airway disorders including pharyngodinia,"/>
  <result pre="mortality [8]; Â°Â° responsible for atypical pneumonia as well as" exact="benign" post="upper airway disorders including pharyngodinia, hoarseness, etc. [10]. microorganisms-08-01228-t002_Table"/>
  <result pre="[8]; Â°Â° responsible for atypical pneumonia as well as benign" exact="upper" post="airway disorders including pharyngodinia, hoarseness, etc. [10]. microorganisms-08-01228-t002_Table 2Table"/>
  <result pre="etc. [10]. microorganisms-08-01228-t002_Table 2Table 2 Characterization of SARS-CoV-1, Middle Eastern" exact="respiratory" post="syndrome (MERS)-CoV, and SARS-CoV-2 spike region, homology with bat"/>
  <result pre="[10]. microorganisms-08-01228-t002_Table 2Table 2 Characterization of SARS-CoV-1, Middle Eastern respiratory" exact="syndrome" post="(MERS)-CoV, and SARS-CoV-2 spike region, homology with bat coronavirus,"/>
  <result pre="MT077125.1 EPI_ISL_406596 (GISAID No.) Reference [37] [38] [39] [33] [40]" exact="Complete" post="genome length (nt) 29,727 30,119 29,903 29,785 29,853 Spike"/>
 </snippets>
</snippetsTree>
